Article in mSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
William C ShropshireDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA.ORCID 0000-0001-8556-3248
Benjamin StropeProgram in Diagnostic Genetics and Genomics, MD Anderson Cancer Center School of Health Professions , Houston, Texas, USA.
Selvalakshmi Selvaraj AnandProgram in Diagnostic Genetics and Genomics, MD Anderson Cancer Center School of Health Professions , Houston, Texas, USA.
Jordan BremerDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA.
Patrick McDaneld *Division of Pharmacy, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA.
Micah M Bhatti *Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA.ORCID 0000-0001-5857-5825
Anthony R FloresDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center , Houston, Texas, USA.ORCID 0000-0002-6402-4269
Awdhesh KaliaProgram in Diagnostic Genetics and Genomics, MD Anderson Cancer Center School of Health Professions , Houston, Texas, USA.
Samuel A ShelburneDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA.ORCID 0000-0001-9721-263X
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0M
Biogenesis of Surface-Exposed Lipoproteins in Gram-Negative BacteriaR01GM133904 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KONOVALOVA, ANNA · 2019 to 2023
$1.6M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
NovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995k
Role of β-lactamase encoding gene amplification in the development of non-carbapenemase producing, carbapenem-resistant EnterobacteriaceaeR21AI151536 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHELBURNE, SAMUEL A · 2021 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Temporal dynamics of genetically heterogeneous extended-spectrum cephalosporin-resistant · full record | OpenQuestion